ASRT

Assertio Holdings, Inc. stock has trended up significantly in the past six months. A reverse stock split was enacted to maintain its Nasdaq listing. A tender offer for acquiring shares was delayed, following an updated merger deal with Garda Therapeutics. The company reported its fourth-quarter and full-year 2025 results, showing lower revenue and a wider net loss, and initiated fiscal 2026 revenue guidance in the range of $110 million to $125 million.